We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mediclinic International Plc | LSE:MDC | London | Ordinary Share | GB00B8HX8Z88 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 501.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMDC
RNS Number : 0838E
Mediclinic International plc
01 July 2019
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
1 July 2019
Notification of Major Interest in Mediclinic International plc shares
NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the Mediclinic International underlying issuer of existing shares to which voting rights are attached(ii) : -------------------------------------------- 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer ---- 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X ---- An acquisition or disposal of financial instruments ---- An event changing the breakdown of voting rights ---- Other (please specify)(iii) : ---- 3. Details of person subject to the notification obligation(iv) Name Genesis Asset Managers, LLP City and country of registered office St. Peter Port, Guernsey (if applicable) 4. Full name of shareholder(s) (if different from 3.)(v) Name N/A -------------------------------------------- City and country of registered office (if applicable) -------------------------------------------- 5. Date on which the threshold was 01st July 2019 crossed or reached(vi) : -------------------------------------------- 6. Date on which issuer notified (DD/MM/YYYY): 01st July 2019 -------------------------------------------- 7. Total positions of person(s) subject to the notification obligation % of voting % of voting rights Total of both Total number rights attached through financial in % (8.A + of voting rights to shares (total instruments 8.B) of issuer(vii) of 8. A) (total of 8.B 1 + 8.B 2) ------------------ --------------------- -------------- -------------------- Resulting situation on the date on which threshold was crossed or reached 0% 0% 0 ------------------ --------------------- -------------- -------------------- Position of previous notification (if applicable) 5.15% 5.15% ------------------ --------------------- -------------- -------------------- 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached(viii) A: Voting rights attached to shares Class/type of Number of voting rights(ix) % of voting rights shares ISIN code (if possible) Direct Indirect Direct Indirect (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) ----------------------------- GB00B8HX8Z88 0 0% ------------------------ ----------------------------- ------------------------- --------------------- SUBTOTAL 8. A 0 0% ------------------------------------------------------- ------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of Expiration Exercise/ Number of voting % of voting financial date(x) Conversion Period(xi) rights that may rights instrument be acquired if the instrument is exercised/converted. ----------- ----------------------------------- -------------------------------- --------------------- SUBTOTAL 8. B 1 ----------------------------------- -------------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of Expiration Exercise/ Physical or Number of % of voting financial date(x) Conversion cash voting rights rights instrument Period (xi) settlement(xii) ---------------- ---------------------- ----------------------- -------------------- SUBTOTAL 8.B.2 ----------------------- -------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii) Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary) Name(xv) % of voting rights % of voting rights Total of both if if it equals or through financial it equals or is is higher than the instruments if it higher than the notifiable threshold equals or is higher notifiable threshold than the notifiable threshold ---------------------- --------------------- ------------------------ 10. In case of proxy voting, please identify: Name of the proxy holder ----------------------------------------------- The number and % of voting rights held ----------------------------------------------- The date until which the voting rights will be held ----------------------------------------------- 11. Additional information(xvi) Following an internal restructuring at Genesis Investment Management LLP ("GIM"), all client arrangements transitioned from Genesis Asset Managers, LLP ("GAM") to GIM with effect from 30 June 2019. From that date, GIM became the investment manager lawfully managing investments for clients, which has triggered notifications under DTR5 for both GAM and GIM in relation to their holdings in Mediclinic International plc Place of completion London, England Date of completion 01(st) July 2019 -----------------
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
The Group's core purpose is to enhance the quality of life.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12 day case clinics and 21 outpatient clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five sub-acute hospitals and 12 day case clinics with more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLUAASRKWABRAR
(END) Dow Jones Newswires
July 01, 2019 10:30 ET (14:30 GMT)
1 Year Mediclinic Chart |
1 Month Mediclinic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions